Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2018 Genitourinary Cancers Symposium

8 - 10 Feb 2018
Moscone West Building, San Fancisco, United States of America
Management of marker negative stage II testicular cancer
Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada
Management of marker negative stage II testicular cancer ( Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada )
16 Mar 2018
Expert insight: Metastatic hormone sensitive prostate cancer latest
Professor Karim Fizazi and Professor Nicholas James
Expert insight: Metastatic hormone sensitive prostate cancer latest ( Professor Karim Fizazi and Professor Nicholas James )
10 Feb 2018
Focus on non-metastatic castration resistant prostate cancer
Professor Noel Clarke and Dr Eric Small
Focus on non-metastatic castration resistant prostate cancer ( Professor Noel Clarke and Dr Eric Small )
10 Feb 2018
Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial ...
Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA
Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )
9 Feb 2018
Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma
Dr Jeffrey Graham - Tom Baker Cancer Centre, Calgary, Canada
Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma ( Dr Jeffrey Graham - Tom Baker Cancer Centre, Calgary, Canada )
9 Feb 2018
Genetic mutations: New therapeutic avenues in metastatic prostate cancer
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Genetic mutations: New therapeutic avenues in metastatic prostate cancer ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
9 Feb 2018
6-factor prognostic model for patients with advanced urothelial carcinoma
Dr Gregory Pond - McMaster University, Hamilton, Ontario
6-factor prognostic model for patients with advanced urothelial carcinoma ( Dr Gregory Pond - McMaster University, Hamilton, Ontario )
9 Feb 2018
Comment: Urothelial cancer research from ASCO GU 2018
Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA
Comment: Urothelial cancer research from ASCO GU 2018 ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )
9 Feb 2018
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and meta...
Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis ( Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK )
9 Feb 2018
Genomic profiling of muscle invasive bladder cancer to predict response to bladd...
Dr David Miyamoto - Massachusetts General Hospital, Boston, USA
Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy ( Dr David Miyamoto - Massachusetts General Hospital, Boston, USA )
9 Feb 2018
Tumour fraction in circulating free DNA as a biomarker of disease dynamics in me...
Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA
Tumour fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer ( Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA )
9 Feb 2018
Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amp...
Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium
Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification ( Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium )
9 Feb 2018
Serum miRNA to predict post-chemotherapy viable disease in testicular non-semino...
Dr Ricardo Leão - University of Toronto, Toronto, Canada
Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumour patients ( Dr Ricardo Leão - University of Toronto, Toronto, Canada )
8 Feb 2018
Radium-223 for bone predominant metastatic castration resistant prostate cancer
Dr Andrew Armstrong - Duke University School of Medicine, Durham, USA
Radium-223 for bone predominant metastatic castration resistant prostate cancer ( Dr Andrew Armstrong - Duke University School of Medicine, Durham, USA )
8 Feb 2018
FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurre...
Dr Eugene Teoh - University of Oxford, Oxford, UK
FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurrent prostate cancer ( Dr Eugene Teoh - University of Oxford, Oxford, UK )
8 Feb 2018
PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future t...
Dr Lauren Harshman - Dana-Farber Cancer Institute, Boston, USA
PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trial ( Dr Lauren Harshman - Dana-Farber Cancer Institute, Boston, USA )
8 Feb 2018
POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance i...
Dr Alison Birtle - Lancashire Teaching Hospitals NHS Foundation Trust, Lancashir...
POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance in upper tract urothelial cancer ( Dr Alison Birtle - Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK )
8 Feb 2018
Updates on non-metastatic castration-resistant prostate cancer
Prof Kurt Miller, Prof Silke Gillessen, Prof Heather Payne and Dr Eric Small
Updates on non-metastatic castration-resistant prostate cancer ( Prof Kurt Miller, Prof Silke Gillessen, Prof Heather Payne and Dr Eric Small )
8 Feb 2018
Latest in adjuvant therapy for renal cell carcinoma
Dr Naomi Haas - University of Pennsylvania, Philadelphia, USA
Latest in adjuvant therapy for renal cell carcinoma ( Dr Naomi Haas - University of Pennsylvania, Philadelphia, USA )
8 Feb 2018
Updates in metastatic prostate cancer
Prof Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou, Prof Nicolas Mottet
Updates in metastatic prostate cancer ( Prof Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou, Prof Nicolas Mottet )
8 Feb 2018
Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for...
Dr Ananya Choudhury - The Christie NHS Foundation Trust, Manchester, UK
Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer ( Dr Ananya Choudhury - The Christie NHS Foundation Trust, Manchester, UK )
8 Feb 2018